European Larynx Organ Preservation Study (ELOS) [MK-3475-C44] (ELOS)
ELOS - Induction Chemotherapy With Docetaxel and Cisplatin Followed by Radiation Compared to Additional PD-1 Inhibition in CPS ≥1 Advanced Laryngeal/Hypopharyngeal Cancer Suitable for Laryngectomy Selected After Early Response Evaluation
Sponsor: Ernst von Bergmann Hospital
Listed as NCT06137378, this PHASE2 trial focuses on Hypopharyngeal Squamous Cell Carcinoma and Laryngeal Cancer and remains actively recruiting participants. Sponsored by Ernst von Bergmann Hospital, it has been updated 5 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
5 versions recorded-
Sep 2025 — Present [monthly]
Recruiting PHASE2
-
Oct 2024 — Sep 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Oct 2024 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Ernst von Bergmann Hospital
- Technical University of Munich
- University of Cologne
- University of Göttingen
- University of Jena
- University of Kiel
- University of Leipzig
- University of Regensburg
- University of Ulm
- Universitätsmedizin Mannheim
- Wuerzburg University Hospital
For direct contact, visit the study record on ClinicalTrials.gov .